What this study is
The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallowing, and quality of life. Specimens are collected to measure glial fibrillary acidic protein (GFAP) levels in cerebrospinal fluid (CSF) and blood. The data obtained from this study will be used for the design of future treatment trials.
Study details
- Sponsor
- Children's Hospital of Philadelphia
- Conditions
- Alexander Disease
- Enrolling
- 200 people
- Starts
- 2016-01-26
- Est. completion
- 2030-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Diagnosed with Alexander Disease
You can't join if
- Other Leukodystrophies will not be enrolled
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openChildren's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Geraldine Liu, MA · Contact267-425-2063liug@chop.edu
- Amy T Waldman, MD, MSCE · Principal investigator
Recruiting
Study team
Sponsor
Children's Hospital of Philadelphia
Study ID 16-012649
Principal investigator
Amy Waldman, MD
Children's Hospital of Philadelphia
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.